NPM1 and acute myeloid leukemia: According to the recent National Comprehensive Cancer Network guidelines, AML patients with FLT3-ITD and NPM1 double mutation (AML FLT3-ITD+/NPM1+) are categorized as favorable and intermediate risk levels, depending on the allelic ratio of FLT3-ITD, for whom allogenic stem cell transplantation (allo-HSCT) is not obligated.